Obesity / Overweight | Unmet Need | US/EU | 2024
The demand for safe and effective obesity drugs is increasing due to the rising prevalence of obesity and the growing interest in incretin therapies, whose efficacy is approaching that of bariatric surgery. Recently, therapies that mimic the effects of GLP-1 and GIP peptides—natural gut hormones that regulate appetite and energy metabolism—have established new benchmarks for weight-loss drugs and are poised to reshape the obesity landscape in the coming years. Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide) are the most advanced antiobesity therapies, providing notably greater weight loss than Novo Nordisk’s Saxenda. Older agents, such as phentermine, Contrave, Qsymia, and Xenical, are losing ground as preferred products despite their lower cost. In this report, we surveyed endocrinologists to evaluate and compare current antiobesity drugs. We also discuss the attributes that new antiobesity drugs should exhibit to serve the obese population and gain a competitive edge in the rapidly growing obesity market.
QUESTIONS ANSWERED
- How do endocrinologists rate current antiobesity drugs, such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound?
- Which drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
- What trade-offs across different clinical attributes and prices are needed from new drugs to be preferred by endocrinologists?
- How can dosing frequency, route of administration, cardiorenal benefit, and weight-loss efficacy influence physician preference?
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 60 U.S. and 32 European endocrinologists fielded in March 2024
Key companies: Novo Nordisk, Eli Lilly, Currax Pharmaceuticals, Vivus, Cheplapharm, H2-Pharma
Key drugs: Wegovy, Zepbound, Contrave / Mysimba, Qsymia, Xenical
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.
KEY FEATURE
The Target Product Profile (TPP) Simulator tool allows for customizable market simulations based on conjoint analysis that depicts how physicians make decisions based on actual behavior rather than opinion. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.
